Table 1 Baseline characteristics of the subjects enrolled in the present study

Number

15

22

16

Age, years

65 ± 2

65 ± 2

0.910

66 ± 2

0.889

0.817

Body mass index, kg/m²

25.0 ± 0.9

23.8 ± 0.7

0.666

25.6 ± 1.0

0.359

0.135

Visceral fat area, cm²

111 ± 14

121 ± 14

0.205

123 ± 14

0.255

0.898

Subcutaneous fat area, cm²

137 ± 18

138 ± 12

0.341

141 ± 11

0.394

0.918

Smoking (none-/ex-/current-smoker), n

8/5/2

9/5/8

0.566

3/4/9

0.149

0.230

Diabetes mellitus, n

9

11

0.644

9

0.879

0.793

Sulfonyl ureas/glinides/biguanides/alpha glucosidase inhibitors/Insulin, n

5/0/1/1/2

7/5/6/1/2

4/0/1/4/2

Hypertension, n

13

16

0.436

11

0.392

0.886

Calcium channel antagonists/angiotensin receptor blockers/β-blockers/diuretics, n

8/2/2/0

13/12/4/2

6/8/6/2

Dyslipidemia, n

7

14

0.430

10

0.525

0.965

Statins/fibrates/ezetimibe/cholestimide, n

5/1/0/0

10/0/1/1

9/1/0/0

Anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n

4/0/2

22/0/22

16/6/10

Family history of CAD, n

2

2

0.753

5

0.392

0.116

Systolic blood pressure, mmHg

134 ± 4

137 ± 4

0.808

139 ± 5

0.981

0.802

Diastolic blood pressure, mmHg

78 ± 2

74 ± 2

0.135

77 ± 3

0.586

0.407

Hemoglobin A1c (NGSP),%

6.9 ± 0.5

6.4 ± 0.2

0.255

6.6 ± 0.4

0.661

0.519

LDL-C, mg/dL

123 ± 6

110 ± 7

0.193

113 ± 9

0.789

0.132

Triglyceride, mg/dL

124 ± 16

152 ± 19

0.290

125 ± 12

0.969

0.273

HDL-C, mg/dL

61 ± 4

57 ± 4

0.352

48 ± 3

0.005*

0.139

Creatinine, mg/dL

0.82 ± 0.04

0.87 ± 0.06

0.880

0.82 ± 0.02

0.475

0.510

Target lesions (LMCA/LAD/LCX/RCA), n

-

0/20/1/1

1/40/13/2

ACC/AHA (Type A/B/C)

-

6/12/4

5/7/4

Procedures (PCI/CABG), n

-

22/0

15/1